Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161454 · ClinicalTrials.gov registry record · Phase 4
Xofluza-Wearables Feasibility-Study
A Phase 4 study of Influenza and Infections, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 498
- Enrollment target
- 1
- Study location
NCT06161454 is a Phase 4 study of Influenza and Infections that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 498 participants, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06161454, a Phase 4 study of Influenza and Infections, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 498 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients.
Conditions Studied
Interventions
- DRUG Baloxavir Marboxil
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161454
The ClinicalTrials.gov registry entry for NCT06161454 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Baloxavir Marboxil is the first listed.
NCT06161454 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06161454 about?
NCT06161454 is a clinical study titled "Xofluza-Wearables Feasibility-Study". The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Cent...
What is the current status of trial NCT06161454?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 498 participants. The study started on 2023-12-14. Estimated completion is 2025-04-30.
What conditions does trial NCT06161454 study?
This clinical trial studies the following conditions: Influenza, Infections, Transplant, Infection Viral, Infection, Coronavirus.
What interventions are being tested in trial NCT06161454?
The interventions under investigation include: Baloxavir Marboxil (DRUG).
Who is sponsoring clinical trial NCT06161454?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161454 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.